AMT-101
Phase 2- Indications
- Ulcerative colitis, Pouchitis, Inflammatory bowel disease
Company intelligence / Profile preview
The lead program AMT‑101 completed four Phase 2 trials in ulcerative colitis. Results showed similar clinical remission rates between drug and placebo arms but demonstrated good tolerability. The second program, AMT‑126 targeting IL‑22 pathways for GI disorders, entered Phase 1a trials with plans for further development that were halted as part of strategic restructuring.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Applied Molecular Transport.